REVENUE (Tables)

3 Months Ended

Jan. 31, 2021

Revenue from Contract with Customer [Abstract]

The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:


	Three Months Ended January 31,
	2021								2020
	Life Sciences and Applied Markets		Agilent CrossLab		Diagnostics and Genomics		Total		Life Sciences and Applied Markets		Agilent CrossLab		Diagnostics and Genomics		Total
	(in millions)
Revenue by Region
Americas	$	224	$	179	$	152	$	555	$	209	$	167	$	118	$	494
Europe	190		147		100		437		167		133		92		392
Asia Pacific	308		206		42		556		262		170		39		471
Total	$	722	$	532	$	294	$	1,548	$	638	$	470	$	249	$	1,357

The following table presents the company’s total revenue disaggregated by end markets and by revenue type:


	Three Months Ended
	January 31,
	2021		2020
	(in millions)
Revenue by End Markets
Pharmaceutical and Biopharmaceutical	$	521	$	423
Chemical and Energy	328		312
Diagnostics and Clinical	216		194
Food	162		130
Academia and Government	142		141
Environmental and Forensics	179		157
Total	$	1,548	$	1,357

Revenue by Type
Instrumentation	$	681	$	593
Non-instrumentation and other	867		764
Total	$	1,548	$	1,357

Contract Liabilities and Changes in Balances

The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the three months ended January 31, 2021:


	Contract Liabilities
	(in millions)

Ending balance as of October 31, 2020	$	446
Net revenue deferred in the period	197
Revenue recognized that was included in the contract liability balance at the beginning of the period	(186)
Change in deferrals from customer cash advances, net of revenue recognized	20

Currency translation and other adjustments	8
Ending balance as of January 31, 2021	$	485